Worked PTA Dose Selection for AUC/MIC

From Simulated Exposure to a Dose Decision

For an antimicrobial whose pharmacodynamic target is based on AUC/MIC, dose selection asks whether a regimen produces adequate exposure for a sufficiently large fraction of the target population. A population mean AUC alone cannot answer that question: two populations with the same mean can have different proportions below the target. Simulation makes the distribution of individual exposures explicit.

This tutorial uses a fully hypothetical antimicrobial and hypothetical model outputs. Its target and candidate regimens illustrate the calculation only; they are not clinical recommendations. The goal is to select the lowest candidate dose satisfying a stated probability-of-target-attainment criterion at every MIC value in a specified range.

Definition: Let $AUC_{24}$ be an individual's 24-hour area under the concentration-time curve, let $MIC$ be the organism's minimum inhibitory concentration, and let $T$ be the required AUC/MIC target. For a fixed MIC value $m$, the probability of target attainment (PTA) under regimen $d$ is $$ PTA(d,m)=P\left(\frac{AUC_{24}(d)}{m}\geq T\right) =P\left(AUC_{24}(d)\geq Tm\right). $$ If AUC is measured in mg·h/L and MIC in mg/L, the ratio and target have units of hours. PTA is a probability over the specified target population and its modeled variability, conditional on the model and assumptions used.

A PTA calculation therefore needs a target $T$, a regimen, a population model for AUC under that regimen, and an MIC value. When a dose must cover a range of MIC values, calculate PTA at each prespecified value. Do not silently replace that task with an average over MIC: averaging requires a separate MIC distribution and answers a different question.

Simulation Setup and Assumptions

For each candidate regimen, a population pharmacokinetic model can generate one predicted AUC value per virtual individual. The individual's covariates and random effects are sampled from the intended population, and the model predicts the AUC for that individual's regimen. The same virtual individuals can be evaluated under each candidate dose when a paired comparison is useful; otherwise, independent simulation samples can be used. In either case, the population represented by the simulation must match the population the dose decision is meant to address.

For the worked analysis, suppose the simulated AUC distribution at each dose is lognormal with a common log-scale standard deviation of $0.30$. The modeled median $AUC_{24}$ is 60, 90, 120, 180, or 240 mg·h/L for doses of 600, 900, 1200, 1800, or 2400 mg, respectively. These hypothetical outputs imply dose-proportional exposure over the candidate range. This is an assumption of this example, not a general property of nonlinear pharmacokinetics.

The selection rule is that estimated PTA must be at least 0.90 at each MIC in the range 0.125, 0.25, 0.5, and 1 mg/L. The target is $T=125$ hours. This rule treats all four MIC values as required checks; it does not assign them population weights. The model is treated as fixed for the main simulation, so Monte Carlo error can be assessed separately from uncertainty in model parameters or in the target itself.

Assumptions to state before interpreting a PTA: The AUC predictions adequately represent the intended population and dosing conditions; the exposure metric is calculated over the relevant interval; the AUC/MIC target is appropriate for the specified antimicrobial context; and the MIC values being tested are correctly specified. If dose proportionality is used to obtain candidate exposures, that relationship must be credible over the dose range. Violating these conditions can make a precise PTA estimate misleading.

Worked Dose Selection Across an MIC Range

For a simulation with $N$ virtual individuals, let $AUC_{24,i}(d)$ be the simulated AUC for individual $i$ under dose $d$. At MIC $m$, count the individuals whose simulated AUC meets or exceeds $Tm$. The estimated PTA is that count divided by $N$. This direct calculation does not require the AUC distribution to be lognormal.

Worked Example: Selecting a Dose Across Four MIC Values

Suppose $N=10{,}000$ hypothetical individuals are simulated under each candidate dose. Applying the target $T=125$ hours gives the following numbers of simulated individuals meeting the target. The entries are illustrative simulation output.

Dose (mg)	PTA at MIC 0.125 mg/L	PTA at MIC 0.25 mg/L	PTA at MIC 0.5 mg/L	PTA at MIC 1 mg/L
600	10000/10000 = 1.000	9847/10000 = 0.9847	4472/10000 = 0.4472	68/10000 = 0.006800
900	10000/10000 = 1.000	9998/10000 = 0.9998	8879/10000 = 0.8879	1395/10000 = 0.1395
1200	10000/10000 = 1.000	10000/10000 = 1.000	9848/10000 = 0.9848	4467/10000 = 0.4467
1800	10000/10000 = 1.000	10000/10000 = 1.000	9998/10000 = 0.9998	8892/10000 = 0.8892
2400	10000/10000 = 1.000	10000/10000 = 1.000	10000/10000 = 1.000	9851/10000 = 0.9851

For example, at 900 mg and MIC $0.5$ mg/L, the required AUC is $$ Tm=125\ \mathrm{h}\times 0.5\ \mathrm{mg/L} =62.5\ \mathrm{mg\cdot h/L}. $$ The simulation records 8,879 of 10,000 AUC values at or above this threshold, so $$ \widehat{PTA}(900,0.5)=\frac{8879}{10000}=0.8879. $$ That estimate is below 0.90, so 900 mg fails the rule. At 1800 mg and MIC $1$ mg/L, the threshold is $125$ mg·h/L and the estimate is $8892/10000=0.8892$, also below 0.90. At 2400 mg, the estimate at MIC $1$ mg/L is $9851/10000=0.9851$, and its estimates at the other MIC values are also at least 0.90. Thus 2400 mg is the lowest candidate dose in this table meeting the stated rule at every listed MIC.

The decision is conditional on the four MIC checks and on the hypothetical model and target. It does not say that 90% of patients will have a clinical response, nor does it establish that the target predicts clinical benefit in a particular setting.

A Distributional Check and a Short Derivation

The direct count is the primary simulation estimate. A distributional calculation is useful as a check on the expected pattern and as a way to understand how the MIC threshold changes PTA. If $AUC_{24}$ is lognormal with median $M$ and log-scale standard deviation $\sigma$, then $\ln(AUC_{24})$ is normally distributed with mean $\ln M$ and standard deviation $\sigma$. For any positive threshold $c$,

Express the target as an AUC threshold.
For fixed MIC $m$, attainment is the event $AUC_{24}\geq Tm$.

Take logarithms.
Because the logarithm is increasing, $AUC_{24}\geq Tm$ is equivalent to $\ln(AUC_{24})\geq\ln(Tm)$.

Standardize.
Under the assumed normal distribution of $\ln(AUC_{24})$, the standardized threshold is $z=[\ln(Tm)-\ln M]/\sigma$. Therefore $PTA=1-\Phi(z)$, where $\Phi$ is the standard normal cumulative distribution function.

This derivation shows why a higher MIC lowers PTA at a fixed dose: it increases $Tm$, and hence increases $z$. It also provides a consistency check for the simulated output, but it should not replace simulation when the predicted AUC distribution is not adequately described by a lognormal distribution.

Worked Example: Checking a PTA Calculation Analytically

At 600 mg, suppose the modeled median AUC is 60 mg·h/L and $\sigma=0.30$. At MIC $0.5$ mg/L, the required AUC is $125\times0.5=62.5$ mg·h/L. The standardized threshold is $$ z=\frac{\ln(62.5/60)}{0.30} =\frac{0.04082}{0.30} \approx 0.1361. $$ Thus $$ PTA=1-\Phi(0.1361)\approx 0.4459. $$ This distributional benchmark is close to the illustrative simulated estimate $0.4472$ in the table. Small differences are expected because a finite simulation sample will not reproduce the theoretical probability exactly.

Monte Carlo Precision and Diagnostics

An estimated PTA is itself subject to Monte Carlo error because it is calculated from a finite number of simulated individuals. If $K$ of $N$ simulated individuals attain the target, then $\widehat{PTA}=K/N$. Under independent simulation draws, its approximate Monte Carlo standard error is $$ SE_{\mathrm{MC}}\approx\sqrt{\frac{\widehat{PTA}(1-\widehat{PTA})}{N}}. $$ This standard error describes simulation sampling variability only. It does not account for uncertainty in the estimated population parameters, model structure, target value, or MIC measurement.

Worked Example: Quantifying Monte Carlo Error

In a separate hypothetical simulation run, suppose 923 of 1,000 virtual individuals meet the AUC/MIC target at a specified dose and MIC. Then $$ \widehat{PTA}=\frac{923}{1000}=0.923, \qquad SE_{\mathrm{MC}} \approx\sqrt{\frac{0.923(1-0.923)}{1000}} =\sqrt{0.000071071} \approx 0.00843. $$ An approximate 95% Monte Carlo interval is $0.923\pm1.96(0.00843)$, or approximately 0.9065 to 0.9395. This interval reflects finite simulation size under the assumed simulation model, not a 95% probability that the true clinical response rate lies in that interval. If the decision threshold were 0.90, this run's approximate Monte Carlo interval is above the threshold, but uncertainty in the model and target would still need separate consideration.

Several checks help identify a calculation that may be going wrong. First, verify each threshold $Tm$, including units: increasing MIC should not decrease the required AUC. Second, within a regimen and a common target population, the simulated PTA should generally be non-increasing as MIC rises, because each higher MIC imposes a higher AUC threshold. Third, increasing dose should usually increase PTA when the model predicts higher exposure under the larger dose. Unexpected reversals may reflect simulation noise, a coding or data-alignment error, or genuine model features that need investigation; they should not be smoothed away without explanation.

When a PTA estimate is close to the criterion, increase the number of simulation draws or report Monte Carlo precision so that a sampling fluctuation is not mistaken for a meaningful pass or fail. Also check that the simulated covariates and random effects represent the intended population, that all candidate regimens use the same target definition, and that no simulated individual is inadvertently omitted from one dose or MIC calculation.

What the Decision Does—and Does Not—Establish

The direct simulation approach is flexible: it can accommodate complex NLME predictions, nonlinear dose-exposure relationships, covariates, and non-normal AUC distributions, provided the model can generate the required individual predictions. A parametric calculation, such as the lognormal benchmark above, is simpler when its distributional assumptions are credible. It can be useful for checking simulation output, but it may misrepresent tail probabilities if the AUC distribution is skewed in another way or has multiple subpopulations. Simulation is not automatically more reliable; its results inherit the assumptions and limitations of the model that generated the AUC values.

A PTA rule also compresses a distribution into a pass-or-fail summary. Selecting the lowest candidate dose that crosses a threshold is a transparent decision rule, but it does not by itself compare toxicity, feasibility, adherence, or clinical outcomes. Nor does a set of MIC-specific PTAs imply a PTA for a population with a particular MIC distribution. That population-level summary would require weighting the MIC-specific probabilities using an appropriate distribution.

Common pitfall: “The mean AUC exceeds $T\times MIC$, so the regimen attains the target.” This is not sufficient: the mean does not determine the fraction of individuals above the threshold. The correction is to evaluate the simulated individual AUC values against $Tm$, calculate the proportion meeting the target, and apply the stated criterion to that proportion.

Check Your Understanding

Answer each question using the target and definitions given above. Brief solutions follow the questions.

For $T=125$ hours and MIC $0.25$ mg/L, what AUC threshold must an individual meet?
If 8,700 of 10,000 simulated individuals meet the target at a particular dose and MIC, what is the estimated PTA, and does it meet a 0.90 criterion?
Why is the PTA at a higher MIC expected to be no greater than the PTA at a lower MIC when the regimen and target are unchanged?
Does a Monte Carlo standard error account for uncertainty in the NLME model parameters? Explain.
If a candidate passes the PTA criterion at MIC 0.125, 0.25, and 0.5 mg/L but fails at 1 mg/L, does it satisfy a rule requiring attainment at every MIC in the listed range?

Solutions. (1) $125\times0.25=31.25$ mg·h/L. (2) The estimate is $8700/10000=0.8700$, below 0.90, so it fails. (3) A higher MIC raises the threshold $Tm$; the event $AUC_{24}\geq Tm$ can only become less likely as that threshold rises. (4) No. The Monte Carlo standard error quantifies finite-simulation variability conditional on the model; parameter and structural uncertainty require separate treatment. (5) No. The stated rule requires every listed MIC to meet the criterion.